Gut bacteriophage dynamics during fecal microbial transplantation in subjects with metabolic syndrome

Show full item record



Permalink

http://hdl.handle.net/10138/337019

Citation

Manrique , P , Zhu , Y , van der Oost , J , Herrema , H , Nieuwdorp , M , de Vos , W M & Young , M 2021 , ' Gut bacteriophage dynamics during fecal microbial transplantation in subjects with metabolic syndrome ' , Gut Microbes , vol. 13 , no. 1 , e1897217 . https://doi.org/10.1080/19490976.2021.1897217

Title: Gut bacteriophage dynamics during fecal microbial transplantation in subjects with metabolic syndrome
Author: Manrique, Pilar; Zhu, Yifan; van der Oost, John; Herrema, Hilde; Nieuwdorp, Max; de Vos, Willem M.; Young, Mark
Contributor organization: Willem Meindert Vos de / Principal Investigator
de Vos & Salonen group
Research Programs Unit
Departments of Faculty of Veterinary Medicine
University of Helsinki
HUMI - Human Microbiome Research
Date: 2021-01-01
Language: eng
Number of pages: 15
Belongs to series: Gut Microbes
ISSN: 1949-0976
DOI: https://doi.org/10.1080/19490976.2021.1897217
URI: http://hdl.handle.net/10138/337019
Abstract: Metabolic Syndrome (MetS) is a growing public health concern worldwide. Individuals with MetS have an increased risk for cardiovascular (CV) disease and type 2 diabetes (T2D). These diseases–in part preventable with the treatment of MetS–increase the chances of premature death and pose a great economic burden to health systems. A healthy gut microbiota is associated with a reduction in MetS, T2D, and CV disease. Treatment of MetS with fecal microbiota transplantation (FMT) can be effective, however, its success rate is intermediate and difficult to predict. Because bacteriophages significantly affect the microbiota membership and function, the aim of this pilot study was to explore the dynamics of the gut bacteriophage community after FMT in MetS subjects. We performed a longitudinal study of stool bacteriophages from healthy donors and MetS subjects before and after FMT treatment. Subjects were assigned to either a control group (self-stool transplant, n = 3) or a treatment group (healthy-donor-stool transplant; n-recipients = 6, n-donors = 5). Stool samples were collected over an 18-week period and bacteriophage-like particles were purified and sequenced. We found that FMT from healthy donors significantly alters the gut bacteriophage community. Subjects with better clinical outcome clustered closer to the heathy donor group, suggesting that throughout the treatment, their bacteriophage community was more similar to healthy donors. Finally, we identified bacteriophage groups that could explain these differences and we examined their prevalence in individuals from a larger cohort of MetS FMT trial. Trial information- http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2705; NTR 2705.
Description: Publisher Copyright: © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
Subject: 3111 Biomedicine
fecal microbial transplant
Gut microbiome bacteriophages
human gut phage metagenomics
metabolic syndrome
VIROME
INTESTINAL MICROBIOTA
DONOR
INSULIN SENSITIVITY
VIRUSES
11832 Microbiology and virology
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
Gut_bacteriopha ... ith_metabolic_syndrome.pdf 3.062Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record